GABRB3
ENSG00000166206
Target class
Ion channel
Chromosome
15
Approved drugs
56
Clinical candidates (approved and in development)
69
- Approved drugs
- 56
- ClinGen gene-disease validity
- Definitive
- Clinical candidates (approved and in development)
- 69
- Chemical probe available
- No
- Target name
- GABRB3
- Gene name
- Gamma-aminobutyric acid type A receptor subunit beta3
- Gene symbol
- GABRB3
- Protein name
- Gamma-aminobutyric acid receptor subunit beta-3 (GABA(A) receptor subunit beta-3) (GABAAR subunit beta-3)
- Gene biotype
- Protein coding
- Gene family
- Gamma-aminobutyric acid type A receptor subunits
- Target class
- Ion channel
- Target type
- Human gene
- Tissues expressed in
- 20
- Highest tissue expression
- 21.47
- Tissue specificity (Gini)
- 0.705
- Tissue specificity (tau)
- 0.868
- KEGG gene identifiers
- hsa:2562
- Protein interaction confidence
- 0.8496
- Protein interaction partners
- 30
- R-HSA-1236394
- R-HSA-977443
- End position
- 26939539
- Start position
- 26543552
- Chromosome
- 15
- Strand
- Reverse
- Postsynaptic cell membrane
- Multi-pass membrane protein . Cell membrane
- Multi-pass membrane protein . Cytoplasmic vesicle membrane .
- PubMed 24909990
- PubMed 35355020
- PubMed 18281286
- PubMed 18514161
- PubMed 22243422
- PubMed 22303015
- PubMed 26950270
- Tissue specificity (tau)
- 0.867881
- Expression inequality (Gini)
- 0.705203
Expression in transcripts per million
- Brain - Frontal Cortex (BA9)
- 21.47
- Brain - Cerebellar Hemisphere
- 16.52
- Brain - Nucleus accumbens (basal ganglia)
- 15.13
- Pituitary
- 13.83
- Brain - Cortex
- 13.69
Expression in transcripts per million
- Brain - Frontal Cortex (BA9)21.47
- Brain - Cerebellar Hemisphere16.52
- Brain - Nucleus accumbens (basal ganglia)15.13
- Pituitary13.83
- Brain - Cortex13.69
- Brain - Cerebellum12.17
- Brain - Anterior cingulate cortex (BA24)10.97
- Brain - Caudate (basal ganglia)10.1
- Brain - Hypothalamus7.74
- Brain - Hippocampus7.4
- Brain - Putamen (basal ganglia)6.87
- Brain - Amygdala6.31
- Thyroid2.89
- Heart - Atrial Appendage2.28
- Testis2.24
- Brain - Substantia nigra2.1
- Stomach1.37
- Brain - Spinal cord (cervical c-1)1.29
- Cervix - Endocervix1.22
- Kidney - Medulla1.05
- Fallopian Tube0.93
- Esophagus - Muscularis0.92
- Ovary0.9
- Nerve - Tibial0.89
- Kidney - Cortex0.82
And 29 more, listed on the interactive page.
- GO:0007165
- GO:0007214
- GO:0051932
- GO:0071420
- GO:1902476
- GO:1904862
- GO:0005886
- GO:0043197
- GO:0045211
- GO:1902711
- GO:0004890
- GO:0022851
- GO:0042802
Related records
Trials (3,915)
- "Chou's Tiaoshen" Acupoints for Short-term Insomnia.
- "Volatile Anesthetic Protection Of Renal Transplants: VAPOR-1-trail
- (Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors
- [18F]Fluciclovine in Post-treatment Glioblastoma ( Axumin )
- 1-1-8 Wash-in for Sevoflurane Low Flow Anesthesia
- 12-Month Real-World Safety & Efficacy of Lecanemab in Early Alzheimer's Disease
- 28-day Repeat Dose and Drug Interaction Study With Orvepitant (GW823296)
- 3 mL Inhaled Methoxyflurane for Intrauterine Device (IUD) Insertion
- 50% Effective Concentration of Sevoflurane for Immobility
- 6-Month Chronic Efficacy & Safety Study of Eszopiclone in Adult Subjects With Primary Insomnia
- A 2-Part Study to Assess Potential Metabolism-Based Drug-Drug Interactions of E2006 When Coadministered With Itraconazole, Rifampin, Midazolam, or Bupropion
- A 5-Week Trial Of PD 0332334 And Alprazolam Extended Release Compared To Placebo In Patients With Generalized Anxiety Disorder
- A Better Choice for Patients Undergoing Endovascular Coil Embolization
- A Bioequivalence and Food Effect Study of SEP-190 in Japanese Healthy Subjects (Study SEP 190-102)
- A Bioequivalence Study Of A New Alprazolam Dropped Formulation Versus Alprazolam Tablets
- A Clinical Drug-Drug Interaction (DDI) Study With Omaveloxolone
- A Clinical Study Evaluating Sedation of Intravenous Administration of HSK3486 in ICU Patients Undergoing Long-Term Mechanical Ventilation
- A Clinical Study of Remimazolam Tosilate Compared to Propofol for General Anesthesia During Elective Surgery
- A Clinical Study of Remimazolam Tosilate in Patients Undergoing Bronchoscopy
- A Clinical Study to Assess Next-day Driving Performance Following Administration of ACT-541468 in Middle-aged and Elderly Subjects
Drugs (79)
- ABP-700 GABA-A receptor; anion channel agonist
- Acamprosate GABA-A receptor; anion channel positive modulator
- Acamprosate calcium GABA-A receptor; anion channel positive modulator
- Adipiplon GABA-A receptor; anion channel partial agonist
- Alprazolam GABA-A receptor; anion channel positive allosteric modulator
- Brexanolone GABA-A receptor; anion channel positive allosteric modulator
- Butabarbital GABA-A receptor; anion channel positive allosteric modulator
- Butabarbital sodium GABA-A receptor; anion channel positive allosteric modulator
- Butalbital GABA-A receptor; anion channel positive allosteric modulator
- Cenobamate GABA-A receptor; anion channel positive allosteric modulator
- Chlordiazepoxide GABA-A receptor; anion channel positive allosteric modulator
- Chlordiazepoxide hydrochloride GABA-A receptor; anion channel positive allosteric modulator
- Cipepofol GABA-A receptor; anion channel agonist
- Clobazam GABA-A receptor; anion channel positive allosteric modulator
- Clomethiazole GABA-A receptor; anion channel positive allosteric modulator
- Clonazepam GABA-A receptor; anion channel positive allosteric modulator
- Clorazepate dipotassium GABA-A receptor; anion channel positive allosteric modulator
- Clorazepic acid GABA-A receptor; anion channel positive allosteric modulator
- Clotiazepam GABA-A receptor; anion channel positive allosteric modulator
- Darigabat GABA-A receptor; anion channel agonist